A University of Houston researcher is developing a light-based technology to analyze tiny particles in the blood for molecular signs of liver cancer. The approach aims to detect the disease at its earliest stages and improve treatment options.
Researchers created a detailed map of the cell environment surrounding early breast cancers, revealing changes in cancer cells and surrounding microenvironment as disease progresses. The study identified previously unknown 'cancer stromal loops' that support tumor growth, providing potential insights for predicting invasive breast canc...
A new review examines the relationship between tumors and the nervous system, suggesting that psychedelics may be able to 'listen' to the system and provide relief from cancer-related symptoms. The review also explores the potential for psychedelics to modulate the immune system and reduce inflammation in cancer patients.
Researchers propose that childhood cancers may spread aggressively by 'shape-shifting' into different cellular states, rather than accumulating genetic mutations. This process may be reversible, and understanding these transitions could lead to new treatment opportunities and potentially predict when cancers are preparing to spread
A new treatment approach combining immunotherapy with targeted cancer drug enfortumab vedotin improves survival in patients with muscle-invasive bladder cancer. The treatment reduces the risk of death by 42% and cancer recurrence or progression by 49% in patients unable to receive standard chemotherapy.
Researchers identified protein DUSP4 that helps maintain cancer-fighting T cells' anti-tumour function, potentially improving CAR-T therapy against colorectal cancer. Lower DUSP4 levels in patients correlate with poorer overall survival.
Dr. El-Khoueiry is an international leader in liver cancer treatment and clinical trials. He will advance USC Norris' mission to translate scientific discoveries into new cancer prevention, diagnosis, and treatment approaches.
A new study published in Cell reveals that perforin, a protein made by T cells and NK cells, can induce ferroptosis in tumor cells, a previously unknown mechanism of cell death. This discovery could have significant implications for understanding how cancers are killed by immune cells and could lead to new avenues for immunotherapy.
Researchers at UCLA Health Jonsson Comprehensive Cancer Center identified a new strategy to strengthen immune cells and improve their ability to kill cancer cells. Temporarily activating p53, a protein that prevents cancer, helps engineered immune cells resist exhaustion and improve their ability to kill tumor cells.
Researchers identified biomarkers for dasatinib therapy in relapsed or refractory T-follicular helper cell lymphoma, associated with treatment response and immune activity. Clinical responses were observed in patients with mutations related to TCR signaling.
A UT San Antonio College of Sciences researcher has developed a novel molecular smart probe that illuminates breast cancer cells during surgery, providing surgeons with cleaner margins and patients lower risk of recurrence. The probe targets proteins in the cells that fuel tumor growth and is paired with an FDA-approved drug to form a ...
Cancers can evade chemotherapy by entering a 'zombie-like state' called premature senescence, which tricks the immune system into helping malignant cells. This phenomenon allows tumours to acquire extra oxygen and nutrients, making them more resistant to chemotherapy.
Researchers developed a diet-based mouse model to study a serious immunotherapy side effect affecting up to 40% of patients. The study found that a protein in unstable immune cells can cause inflammation, which can be reversed by shutting off the protein or switching to a high fiber diet.
Researchers at UCLA Health Jonsson Comprehensive Cancer Center used CRISPR screen to identify key molecular pathway driving T-cell exhaustion in cancer-fighting immune cells. Disabling the pathway, CRL5, allowed engineered immune cells to stay active longer and fight solid tumors more effectively in preclinical studies.
Researchers at the University of Nottingham discovered how a common genetic mutation disrupts protein positioning during cell division, contributing to acute myeloid leukemia. They found that manipulating the chromosome periphery could help restore normal protein positioning and potentially complement existing therapies.
UChicago Medicine launches a groundbreaking clinical trial testing a new personalized cell therapy for advanced solid tumors, including ovarian cancer and melanoma. The treatment uses specially engineered T-cell receptors to detect hidden cancer proteins, expanding the number of cancers that can be targeted.
Researchers found that specific combinations of TP53 and CDKN2A mutations activate cGAS-STING-mediated immunity, delaying oral cancer progression. The immune activation was associated with delayed progression to invasive oral cancer.
Researchers discovered that the immune system ages differently in biological males and females, with males experiencing earlier decline in T cell immunity and impaired anti-cancer responses. The study's findings suggest that understanding age and sex differences in cancer immunity can lead to more individualized treatment decisions.
An international team identified ST6GAL1 as a key driver of glycocalyx remodeling, which shifts macrophages from an immunosuppressive state to a tumor-fighting state. Suppression of ST6GAL1 inhibited tumor growth in laboratory co-cultures, suggesting a potential strategy for cancer immunotherapy.
Researchers identify key role of spatial niche in early gastric cancer initiation and progression, highlighting inflammation-associated spatial niche as fundamental regulatory unit. Targeting inflammation-associated spatial niches may enable earlier and more precise therapeutic strategies.
The review proposes co-designing oncolytic viruses and CAR cells to overcome solid tumor barriers, enabling a self-amplifying therapeutic system. Oncolytic viruses can be engineered to deliver payloads, expanding target recognition and maintaining CAR cell function.
The UVA Weber Symposium will discuss the latest research and advancements in metastasis, a complex area of cancer research and care. The event will bring together top scientists and physicians to present findings on cancer metastasis, genetics, and treatment considerations.
Researchers at UT MD Anderson Cancer Center have made significant breakthroughs in cancer treatment, developing a targeted antibody that improves outcomes for patients with advanced lung cancer who have faced treatment resistance. The treatment, which combines ivonescimab with chemotherapy, has been shown to extend disease control and ...
A Phase 1 clinical trial found that an investigational CAR-T therapy, anito-cel, led to high response rates and durable benefits in patients with relapsed/refractory multiple myeloma. Serious side effects were uncommon, and no delayed neurological complications were reported.
Researchers found similar diarrhea outcomes among patients with low and normal fecal elastase levels, suggesting stool dilution is a possible cause. Fecal fat testing is recommended before enzyme therapy to confirm exocrine pancreatic insufficiency.
A new, incisionless liver cancer treatment called histotripsy was associated with low rates of laboratory toxicity and procedural complications in a real-world review of 972 patients. However, the study found that 11% of patients died within 30 days, suggesting that advanced cancer and overall disease burden may be contributing factors.
Researchers identified a previously unknown pathway that prostate tumors leverage to suppress the immune system, reshaping the tumor microenvironment to resist treatment. Combining B7-H3-targeted therapy with MEK inhibition improved antitumor responses and prolonged survival in preclinical models of castration-resistant prostate cancer.
Researchers from City of Hope have developed a 'plug-and-play' CAR T technology that allows scientists to update engineered cancer-fighting immune cells after treatment. This technology, called meditope, enables the cells to adapt as tumors evolve, helping them to better control the cells and redirect them to attack different types of ...
The Alliance for Clinical Trials in Oncology is hosting a public webinar highlighting key findings from Alliance and Alliance Foundation Trials studies presented at the 2026 ASCO Annual Meeting. The webinar will feature treatment advances for breast, lung, and prostate cancers, and will include patient representatives to provide insigh...
Researchers develop nanoparticles that target tumor-associated macrophages, reprogramming them to attract cancer-fighting T cells. The approach shows promise in reducing immune-suppressing macrophages and increasing cancer-fighting T cells, with potential for improving immunotherapy for solid cancers.
The 2026 Josep Carreras Institute Symposium explores the latest immunology advances in haematological malignancies, transforming treatment landscapes with CAR-T therapies and checkpoints. Major challenges remain in understanding tumour-immune system interactions and therapeutic resistance.
Researchers found that longer-lived bats have higher levels of cancer-fighting genes and an immune system that can mount an overwhelming attack against infectious organisms and cancer. This discovery suggests that understanding one will help scientists understand the other.
Researchers have developed an mRNA immunotherapy that eliminates pancreatic tumors in mice, achieving complete tumor responses and long-term disease-free periods. The treatment uses a cocktail of immune cytokine and tumor-associated antigen mRNAs, showing promise as a potential transformative treatment for pancreatic cancer.
Researchers found that tumors can damage peripheral nerves before chemotherapy begins, leading to potential nerve damage and chronic pain. The study challenges the conventional thought that peripheral neuropathy is mostly due to chemotherapy treatment.
Researchers from the University of Osaka have found a rare type of immune cell that expands in supercentenarians, potentially helping protect against cancer and other age-related threats. The cells, known as CD4 CTLs, have been shown to be highly active and may help the body cope with persistent threats that increase with age.
Researchers at Pusan National University investigated how chronic environmental stress drives immune dysfunction in cold tumors, revealing a key driver of NK-cell maladaptation: the GDF15-AhR axis. This axis sustains activation of stress-sensing receptors, gradually exhausting NK cells and enabling immune escape.
The Alliance for Clinical Trials in Oncology emphasizes the significance of clinical trials in advancing breast cancer treatments and early detection. The organization's work has led to a 44% decline in breast cancer mortality rates among women since 1989.
Researchers identify IL-26 as a key regulator that reprograms tumor cells to evade immune attack, promoting immune escape and resistance to anti-PD-1 therapy. Targeting IL-26 may improve immunotherapy outcomes and lead to new treatments for cancer and chronic inflammatory diseases.
Research at UT MD Anderson Cancer Center has identified biomarkers to identify patients with resectable NSCLC who benefit most from perioperative immunotherapy. The center also found that the composition of donor cord blood may influence CAR NK cell therapy outcomes.
Recent research found that D-serine accelerates gastric cancer growth by suppressing cytotoxic T-cell activity and promoting immunosuppressive macrophages. High serum D-serine concentrations were linked to ICI therapy resistance in patients, suggesting its potential as a biomarker for disease progression.
Cancer cells' ability to evade the immune system is linked to changes in their surrounding environment, including nearby nutrients and conditions. Researchers discovered that altering these factors can thin the cancer cell's protective sugar coating, allowing the immune system to recognize and eliminate them.
Researchers at UCLA Health Jonsson Comprehensive Cancer Center are developing drug-based strategies to enhance cancer immunotherapy for melanoma and potentially other cancers. They identified two promising compounds that could strengthen T cell interaction with cancer cells or make tumor cells more susceptible to destruction by T cells.
The Alliance QUANTUM trial is testing whether post-transplant consolidation therapy with teclistamab improves survival in patients with primary plasma cell leukemia. Plasma cell leukemia is a rare but aggressive blood cancer with poor long-term survival rates.
Researchers found that chemotherapy triggers an inflammatory cascade recruiting immune cells to protect the tumor, leading to chemoresistance. Blocking this pathway with existing drugs may restore chemotherapy sensitivity.
Researchers discover how tumors hijack the thymus to evade immune surveillance by transporting tumor antigens there. Disrupting a specific chemokine receptor may enhance anti-tumor immunity and improve cancer treatment outcomes.
A new study reveals that p53 mutations in cancer cells can limit the effectiveness of immunotherapy by manipulating cellular metabolism, specifically through autophagy. Removing these mutant forms of p53 restores mTORC1 activity and reduces autophagy, making tumors more vulnerable to immune attack.
Scientists at UVA have developed a new method to target glioblastoma, the most common and deadly brain cancer, by delivering microRNAs through the brain's natural barrier. The approach shows promise in slowing tumor growth and extending survival in animal models.
Researchers at UT MD Anderson Cancer Center have made significant progress in treating rare brain infections with a virus-specific T cell therapy, achieving an overall response rate of 56.8% in patients with progressive multifocal leukoencephalopathy (PML). The center also introduced a novel CAR T cell therapy for hard-to-treat kidney ...
The emerging role of ZBP1 in cancer therapy involves converting genomic stress into potent antitumor immunity. Therapeutic activation of the ZBP1 pathway may transform immunologically "cold" tumors into "hot" tumors by inducing immunogenic necroptosis, stimulating robust immune responses.
A study published in Cancer Research identified an immune pathway that promotes the progression of oral precancerous lesions into head and neck squamous cell carcinoma. The researchers found that targeting a key inflammation signal known as interleukin-1 alpha (IL-1α) could help restore immune surveillance and prevent high-risk lesions...
A study published in Science reveals that dendritic cells build and maintain structures called tertiary lymphoid structures (TLSs) within tumors, which serve as local command centers for the immune system. These hubs play a key role in antitumor immunity and may be a target for future therapies.
A buildup of bile acids caused by an unhealthy gut can drive breast cancer to other parts of the body, researchers reveal. The study found that replenishing beneficial bacteria or treating patients with FDA-approved bile acid sequestrants may reduce breast cancer metastasis.
Sylvester researchers develop AI-powered fracture prediction models, train as wildland firefighters to reduce cancer risk, and discover new targets for pancreatic cancer treatment. A new tumor-on-a-chip model shows how pancreatic cancer hijacks immune cells.
Scientists at MD Anderson Cancer Center have identified a previously unknown mechanism by which T cells attack and eliminate acute myeloid leukemia (AML) cells. The discovery reveals that AML cells use a CD64-dependent pathway to evade traditional MHC recognition, potentially explaining why AML is sensitive to immune-based treatments.
Researchers created a comprehensive single-cell map of the tumor immune microenvironment in multiple myeloma and its precursor conditions. The study identified five distinct subtypes, or 'ecotypes,' that capture meaningful insights into signaling pathways and genetic programs not fully explained by disease stage alone.
A multidisciplinary consensus updates treatment guidance for prolactinomas, emphasizing early recognition, individualized management strategies, and advanced imaging. The recommendations cover screening, assessment, diagnosis, treatment, and long-term monitoring to improve patient outcomes and quality of life.
Researchers found that yeast-based supplements can reprogram early-stage immune cells to produce enhanced anti-tumor responses. The study suggests a potential solution for obesity-related immune dysfunction and cancer, using a food-grade supplement with an excellent safety record.
A study published in Cancer Cell identified a six-gene signature in microscopic colorectal cancer liver metastases that may help predict recurrence after treatment. The findings suggest these tiny tumor deposits could serve as a tissue-based marker of residual cancer cells, recurrence risk and chemotherapy resistance.
A new method called ATTACH identifies strong interactions between T cells and cancer-specific proteins to isolate effective tumor-reactive T cells. This approach overcomes key challenges in immunotherapy development, offering a rapid and accessible way for isolating rare immune cells.
The new journal features cutting-edge research across basic, clinical, and translational immunology. It is designed to connect researchers across the full breadth of immunology, deepening understanding of the immune system in health and disease.